Sustained Therapeutics Inc.
Sustained Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative sustained-release drug delivery platforms for the treatment of pain, cancer, and inflammatory diseases. Their mission is to translate advanced technologies into clinical solutions that help patients manage acute and chronic conditions more effectively and with fewer side effects.
Industries
Nr. of Employees
small (1-50)
Sustained Therapeutics Inc.
Jack Bell Research Centre, 2660 Oak Street, Vancouver, BC V6H 3Z6
Products
ST-01 (sustained-release lidocaine formulation)
A sustained-release formulation of lidocaine designed for local injection to provide prolonged analgesia for acute and chronic pain indications.
ST-02 (sustained-release gemcitabine formulation)
A sustained-release formulation of gemcitabine intended for direct delivery to the upper urinary tract via catheter to coat tissue and extend local chemotherapy exposure.
ST-04 (sustained-release alprostadil) - under development
A sustained-release formulation under development intended to deliver alprostadil for local treatment of erectile dysfunction.
ST-01 (sustained-release lidocaine formulation)
A sustained-release formulation of lidocaine designed for local injection to provide prolonged analgesia for acute and chronic pain indications.
ST-02 (sustained-release gemcitabine formulation)
A sustained-release formulation of gemcitabine intended for direct delivery to the upper urinary tract via catheter to coat tissue and extend local chemotherapy exposure.
ST-04 (sustained-release alprostadil) - under development
A sustained-release formulation under development intended to deliver alprostadil for local treatment of erectile dysfunction.
Services
Sponsorship and operational execution of early- and mid-stage clinical trials including site selection, patient recruitment, and study coordination across multiple Canadian centers.
Preclinical and formulation development services to match polymer systems with drug candidates, including flowability, setting, and release-profile tuning.
Sponsorship and operational execution of early- and mid-stage clinical trials including site selection, patient recruitment, and study coordination across multiple Canadian centers.
Preclinical and formulation development services to match polymer systems with drug candidates, including flowability, setting, and release-profile tuning.
Expertise Areas
- Sustained-release drug delivery development
- Formulation development and optimization
- Clinical trial management (Phase I–III, multi-center)
- Local targeted administration techniques
Key Technologies
- Sustained-release polymer gel formulations
- In situ gelling injectable depots
- Catheter-based local drug administration
- Controlled-release formulation tuning
News & Updates
The first patient has entered the Phase II/III trial of ST-02 targeting Upper Tract Urethral Carcinoma (UTUC). The trial aims to evaluate the efficacy of a sustained release formulation of the drug delivered directly to the site of the cancer.
Regulatory clearance for a pivotal Phase II/III trial of a new medication for a rare form of cancer, UTUC, has been granted. The product, ST-02, is delivered directly to the site of the carcinoma in the renal pelvis.
A Phase II clinical trial is recruiting men with chronic scrotal pain to test a sustained-release lidocaine formulation. The trial aims to determine the effectiveness of repeat injections in reducing pain.
A Phase I trial demonstrated the safety, tolerability, and efficacy of a long-lasting local anesthetic in patients with chronic scrotal content pain.
A second Phase II trial of a long-lasting non-opioid pain medication, ST-01, is underway for treating Chronic Scrotal Pain, which affects about 5% of men.
The company has received regulatory approval to begin a second Phase II trial of its long-lasting non-opioid pain medication, evaluating a sustained release platform technology.
The first patient has entered the Phase II/III trial of ST-02 targeting Upper Tract Urethral Carcinoma (UTUC). The trial aims to evaluate the efficacy of a sustained release formulation of the drug delivered directly to the site of the cancer.
Regulatory clearance for a pivotal Phase II/III trial of a new medication for a rare form of cancer, UTUC, has been granted. The product, ST-02, is delivered directly to the site of the carcinoma in the renal pelvis.
A Phase II clinical trial is recruiting men with chronic scrotal pain to test a sustained-release lidocaine formulation. The trial aims to determine the effectiveness of repeat injections in reducing pain.
A Phase I trial demonstrated the safety, tolerability, and efficacy of a long-lasting local anesthetic in patients with chronic scrotal content pain.
A second Phase II trial of a long-lasting non-opioid pain medication, ST-01, is underway for treating Chronic Scrotal Pain, which affects about 5% of men.
The company has received regulatory approval to begin a second Phase II trial of its long-lasting non-opioid pain medication, evaluating a sustained release platform technology.